web analytics
4.7 C
Tuesday, November 29, 2022

The Real Story on Relmada Therapeutics Inc (OTCMKTS:RLMD)

Relmada Therapeutics Inc (OTCMKTS:RLMD) has continued to trade lower in recent months moving back towards its 52-week lows of $1.01.

The stock has not fared well since the 1 for 5 reverse stock split in August and was the subject of a hard mailer promotion from Gramercy Strategic Partners LLC with a disclosed budget of $964,391; and a mailer made to look like a newspaper mock up.

Relmada Therapeutics Inc (OTCMKTS:RLMD) is a clinical-stage specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain.

Relmada Therapeutics has a diversified portfolio of four lead products at various stages of development including d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine; BuTab, its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol.

The Company’s product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company’s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.

Back in February RLMD announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct a pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab) being developed for the treatment of both chronic moderate to moderately severe pain and opioid dependence.

To Find out the inside Scoop on RLMD Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

The Company is planning a Phase 1 study designed to assess the safety, tolerability, and pharmacokinetics of BuTab in healthy subjects. The safety and pharmacokinetic data from this study will inform the design of subsequent clinical pharmacology studies for opioid dependence and potential regulatory filing for this indication along with the design of a Phase 3 study in chronic pain under the abbreviated 505(b)(2) regulatory pathway.

In March the Company said it has received a No Objection Letter (“NOL”) from Health Canada to conduct the first pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab, REL-1028) being developed for the treatment of both chronic pain and opioid dependence.

CEO Sergio Traversa remarked “Following Health Canada clearance, our second product candidate is about to enter clinical trials during the second quarter of 2015. The rapid progress of our pain relief portfolio this year is a testament to the experienced and talented team we have in place at Relmada Therapeutics. If we can demonstrate that oral BuTab compares favorably with currently marketed sublingual formulations of buprenorphine, we believe that it has significant commercial potential.”

On July 6 RLMD announced it has been granted a patent from the European Patent Office (EPO) for compositions and methods of use for its extended release oral levorphanol (3-hydroxy-N-methylmorphinan). The Patent (EP 2 448 406 B1), titled “Extended Release Oral Pharmaceutical Compositions of 3-hydroxy-N-methylmorphinan” broadly covers Relmada’s SECUREL™ technology platform and LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules). The patent is not scheduled to expire until 2030.

“This new patent is Relmada’s first European patent providing exclusivity for LevoCap ER and significantly strengthens the Company’s overall patent portfolio and supports our continuing development program,” said Sergio Traversa, CEO of Relmada Therapeutics. “The issuance of this patent also further increases the value proposition of our pain therapy franchise and positions the Company better for strategic partnering opportunities.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $32 million market valuation RLMD has an outstanding balance sheet with minimal debt and $31 million dollars sitting in the treasury. The stock has dropped big in recent months following the 5 for 1 reverse stock split as well as the Gramercy Strategic Partners $964,391 mailer promotion. But RLMD is an exciting story in small caps; the Company is developing novel therapies for the treatment of chronic pain and insiders all point to strong underlying science behind the Company. We will be updating on RLMD on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with RLMD.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in RLMD either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.